Reddy J K, Rao M S
Arch Toxicol Suppl. 1987;10:43-53. doi: 10.1007/978-3-642-71617-1_4.
Significant increases in the number of peroxisomes and in the activity of H2O2 generating peroxisomal fatty acid beta-oxidation enzyme system occur in liver parenchymal cells of mice, rats and certain other species exposed to several structurally dissimilar hypolipidemic drugs and certain phthalate-ester plasticizers. These agents, referred to as peroxisome proliferators, are considered as novel hepatocarcinogenic agents in view of their non-mutagenic and non-genotoxic nature. The lack of mutagenicity of these agents combined with consistent coupling of proliferation of H2O2 generating peroxisomes led to the hypothesis that persistent proliferation of peroxisomes serves as an endogenous initiator of neoplastic transformation by inducing oxidative stress. The mechanism by which oxidative stress leads to neoplastic transformation is, however, not clear. This postulated link between peroxisome proliferation and carcinogenicity implies that tumors should develop only in organs displaying profound peroxisome proliferation. Current evidence indicates that maximal peroxisome proliferation is a tissue-specific phenomenon, restricted largely to the hepatocyte. This tissue-specific biological response suggests that interaction of these structurally dissimilar xenobiotics with a receptor(s) might be the mechanism responsible for peroxisome proliferation and the selective increase in the rate of transcription of peroxisomal fatty acid beta-oxidation enzyme genes without significantly affecting the transcriptional rate of peroxisomal marker enzyme catalase gene. Identification and molecular characterization of peroxisome proliferator specific receptor(s) and elucidation of the mechanisms responsible for the differences in interspecies responses will be necessary for the evaluation of the implications for human health, since the carcinogenicity is not directly attributable to the chemical but to the adaptive responses of the host.
在接触几种结构不同的降血脂药物和某些邻苯二甲酸酯类增塑剂的小鼠、大鼠及其他某些物种的肝实质细胞中,过氧化物酶体数量显著增加,产生过氧化氢的过氧化物酶体脂肪酸β氧化酶系统的活性也显著增强。这些物质被称为过氧化物酶体增殖剂,鉴于其非致突变和非基因毒性的性质,被认为是新型肝癌致癌物。这些物质缺乏致突变性,再加上产生过氧化氢的过氧化物酶体增殖持续存在,导致了这样一种假说,即过氧化物酶体的持续增殖通过诱导氧化应激作为肿瘤转化的内源性启动因素。然而,氧化应激导致肿瘤转化的机制尚不清楚。过氧化物酶体增殖与致癌性之间的这种假定联系意味着肿瘤应该只在过氧化物酶体大量增殖的器官中发生。目前的证据表明,最大程度的过氧化物酶体增殖是一种组织特异性现象,主要局限于肝细胞。这种组织特异性生物学反应表明,这些结构不同的外来化合物与一种或多种受体的相互作用可能是过氧化物酶体增殖以及过氧化物酶体脂肪酸β氧化酶基因转录速率选择性增加而不显著影响过氧化物酶体标记酶过氧化氢酶基因转录速率的机制。为了评估对人类健康的影响,有必要鉴定和分子表征过氧化物酶体增殖剂特异性受体,并阐明物种间反应差异的机制,因为致癌性并非直接归因于化学物质,而是归因于宿主的适应性反应。